OncoDxRx Reveals New Breakthrough OncoMRD BREAST Test
For the first time, OncoDxRx has presented its most advanced minimal residual disease (MRD) technology, the OncoMRD BREAST test, in the prestigious journal Onco (https://www.mdpi.com/2673-7523/5/3/35) published by MDPI.
- (1888PressRelease) July 15, 2025 - This marks the debut appearance of the technology in a highly recognized journal, highlighting its key milestone into operational service. The unveiling in Onco underscores the technology's importance in OncoDxRxs precision diagnostics strategy and affirms the companys determination to showcase revolutionary MRD monitoring capabilities to both the clinical and industrial players.
The OncoMRD BREAST represents the backbone of the cell-free mRNA (cfmRNA) program, OncoDxRxs ambitious initiative to improve and digitize MRD detection and tracking. The OncoMRD BREAST features substantial enhancements over the current NGS somatic mutation detection, including a fully integrated patient-derived gene signature, improved signal capturing from both tumor and non-tumor microenvironment (TME), and advanced scoring systems. These updates allow the assay to detect accurately tumor activities beyond DNA sequences, ensuring faster turnaround and personalized treatment planning in high-complexity situations. OncoMRD BREASTs operational performance is further boosted by cfmRNA profiling (hundreds of copies per cell), ensuring superior detection on diverse clinical samples.
The public appearance of the OncoMRD BREAST is a symbolic affirmation of OncoDxRx's strategic priorities, emphasizing sovereignty, exclusivity, technological superiority, and easy implementation. OncoDxRx has begun a new era of precision theranostics, preparing its technologies for multi-domain and patient-centric clinical environments. The publication of OncoMRD BREAST also served as a demonstration of OncoDxRxs expertise and knowhow, highlighting its capacity to deliver on-time and lab-ready MRD solutions for the twenty-first century.
At the heart of OncoMRD BREAST is the gene signature, a personalized gene expression profile that transforms tumor activities into a fully digitalized score. The score enables real-time data quantification and interpretation, enhancing situational awareness and operational responsiveness.
Compared to NGS mutation detection, the new OncoMRD BREAST is not just a more sensitive or quicker turnaround test; it is an entirely new node in OncoDxRxs precision Dx ecosystem. Its capability to prioritize tumor biomarkers, synchronize TME signal detection and digitalize gene signature elevates OncoMRD BREAST to meet both classical and unconventional residual tumor activities. The result is a platform that not only retains the detection legacy of cfmRNA but also evolves it into a frontline enabler for faster, easier and cheaper MRD monitoring in breast cancer.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam